Trial Outcomes & Findings for Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy (NCT NCT00955201)

NCT ID: NCT00955201

Last Updated: 2019-10-02

Results Overview

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

45 participants

Primary outcome timeframe

Baseline, 12, and 24 weeks

Results posted on

2019-10-02

Participant Flow

Edward Hines Jr. VA Hospital from January 2010-May 2014.

Prior to group randomization, all consenting subjects underwent two separate symptom-limited treadmill stress tests to unmask potentially life-threatening indolent cardiac and/or respiratory disease limitations

Participant milestones

Participant milestones
Measure
Sedentary
Sedentary Control Group
Aerobic Exercise
Structured aerobic exercise (treadmill).
Strength Exercise
Structured isokinetic strength exercise (dynameter).
Combined Aerobic and Strength
Structured aerobic exercise (treadmill) plus structured isokinetic strength exercise (dynameter).
Overall Study
STARTED
12
11
11
11
Overall Study
COMPLETED
8
11
10
7
Overall Study
NOT COMPLETED
4
0
1
4

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sedentary
n=12 Participants
Sedentary Control Group
Aerobic Exercise
n=11 Participants
Structured aerobic exercise (treadmill).
Strength Exercise
n=11 Participants
Structured isokinetic strength exercise (dynameter).
Combined Aerobic and Strength
n=11 Participants
Structured aerobic exercise (treadmill).plus structured isokinetic strength exercise (dynameter).
Total
n=45 Participants
Total of all reporting groups
Age, Continuous
61.0 years
STANDARD_DEVIATION 7.0 • n=99 Participants
61.9 years
STANDARD_DEVIATION 8.3 • n=107 Participants
64.2 years
STANDARD_DEVIATION 9.5 • n=206 Participants
63.0 years
STANDARD_DEVIATION 6.6 • n=7 Participants
62.5 years
STANDARD_DEVIATION 1.4 • n=31 Participants
Sex: Female, Male
Female
0 Participants
n=99 Participants
1 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
2 Participants
n=31 Participants
Sex: Female, Male
Male
12 Participants
n=99 Participants
10 Participants
n=107 Participants
11 Participants
n=206 Participants
10 Participants
n=7 Participants
43 Participants
n=31 Participants
Race/Ethnicity, Customized
Caucasian
6 Participants
n=99 Participants
7 Participants
n=107 Participants
6 Participants
n=206 Participants
7 Participants
n=7 Participants
26 Participants
n=31 Participants
Race/Ethnicity, Customized
African American
6 Participants
n=99 Participants
3 Participants
n=107 Participants
4 Participants
n=206 Participants
3 Participants
n=7 Participants
16 Participants
n=31 Participants
Race/Ethnicity, Customized
Hispanic
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
1 Participants
n=7 Participants
3 Participants
n=31 Participants
Region of Enrollment
United States
12 Count of Participants
n=99 Participants
11 Count of Participants
n=107 Participants
11 Count of Participants
n=206 Participants
11 Count of Participants
n=7 Participants
45 Count of Participants
n=31 Participants

PRIMARY outcome

Timeframe: Baseline, 12, and 24 weeks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation. Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sural Nerve Amplitude
Baseline
0.86 uV
Standard Deviation 1.93
1.22 uV
Standard Deviation 2.93
2.37 uV
Standard Deviation 4.20
0.88 uV
Standard Deviation 2.92
Sural Nerve Amplitude
12 weeks
1.21 uV
Standard Deviation 2.41
2.88 uV
Standard Deviation 3.84
1.49 uV
Standard Deviation 2.58
0.58 uV
Standard Deviation 1.83
Sural Nerve Amplitude
24 weeks
0.65 uV
Standard Deviation 1.84
2.17 uV
Standard Deviation 3.28
2.93 uV
Standard Deviation 3.39
0.86 uV
Standard Deviation 2.72

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sural Nerve Latency
Baseline
0.64 ms
Standard Deviation 1.43
0.61 ms
Standard Deviation 1.43
1.01 ms
Standard Deviation 1.73
0.39 ms
Standard Deviation 1.3
Sural Nerve Latency
12 weeks
0.89 ms
Standard Deviation 1.76
1.41 ms
Standard Deviation 1.83
1.04 ms
Standard Deviation 1.79
0.42 ms
Standard Deviation 1.33
Sural Nerve Latency
24 weeks
0.48 ms
Standard Deviation 1.34
1.26 ms
Standard Deviation 1.91
1.57 ms
Standard Deviation 1.86
0.4 ms
Standard Deviation 1.26

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sural Nerve Conduction Velocity
baseline
7.35 m/s
Standard Deviation 16.38
6.21 m/s
Standard Deviation 14.5
11.1 m/s
Standard Deviation 19.26
3.27 m/s
Standard Deviation 10.85
Sural Nerve Conduction Velocity
12 weeks
8.62 m/s
Standard Deviation 17.14
16.46 m/s
Standard Deviation 21.32
10.55 m/s
Standard Deviation 18.24
3.73 m/s
Standard Deviation 11.8
Sural Nerve Conduction Velocity
24 weeks
5.34 m/s
Standard Deviation 15.10
12.38 m/s
Standard Deviation 18.63
18.54 m/s
Standard Deviation 21.48
3.88 m/s
Standard Deviation 12.27

PRIMARY outcome

Timeframe: Baseline, 12 weeks, 24 weeks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Tibial Nerve Amplitude
Baseline
4.71 mV
Standard Deviation 3.73
2.97 mV
Standard Deviation 3.13
3.71 mV
Standard Deviation 3.91
3.35 mV
Standard Deviation 3.43
Tibial Nerve Amplitude
12 wks
3.59 mV
Standard Deviation 3.75
3.26 mV
Standard Deviation 3.32
3.03 mV
Standard Deviation 3.39
3.73 mV
Standard Deviation 3.93
Tibial Nerve Amplitude
24 wks
3.33 mV
Standard Deviation 3.68
3.48 mV
Standard Deviation 3.62
3.46 mV
Standard Deviation 3.57
3.90 mV
Standard Deviation 4.04

PRIMARY outcome

Timeframe: Baseline, 12 weeks, 24 weeks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Tibial Nerve Latency
Baseline
4.11 ms
Standard Deviation 1.47
4.37 ms
Standard Deviation 1.5
5.03 ms
Standard Deviation 0.72
4.43 ms
Standard Deviation 1.56
Tibial Nerve Latency
12 wks
4.29 ms
Standard Deviation 1.78
4.15 ms
Standard Deviation 1.62
4.65 ms
Standard Deviation 1.62
4.28 ms
Standard Deviation 1.65
Tibial Nerve Latency
24 wks
5.29 ms
Standard Deviation 1.76
4.41 ms
Standard Deviation 1.7
5.25 ms
Standard Deviation 0.57
4.40 ms
Standard Deviation 2.43

PRIMARY outcome

Timeframe: Baseline, 12 weeks, 24 weeks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Tibial Nerve Conduction Velocity
Baseline
30.43 m/s
Standard Deviation 10.58
31.81 m/s
Standard Deviation 10.42
33.15 m/s
Standard Deviation 4.01
30.0 m/s
Standard Deviation 10.29
Tibial Nerve Conduction Velocity
12 wks
31.08 m/s
Standard Deviation 11.9
32.56 m/s
Standard Deviation 12.51
30.77 m/s
Standard Deviation 11.05
30.64 m/s
Standard Deviation 11.52
Tibial Nerve Conduction Velocity
24 wks
31.73 m/s
Standard Deviation 5.58
30.22 m/s
Standard Deviation 13.43
34.22 m/s
Standard Deviation 4.17
28.51 m/s
Standard Deviation 15.85

PRIMARY outcome

Timeframe: Baseline, 12, and 24 weeks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sensory Median Nerve Amplitude
Baseline
7.18 uV
Standard Deviation 6.88
3.14 uV
Standard Deviation 4.44
5.55 uV
Standard Deviation 8.12
6.91 uV
Standard Deviation 4.61
Sensory Median Nerve Amplitude
12 weeks
6.10 uV
Standard Deviation 6.99
2.41 uV
Standard Deviation 3.23
6.00 uV
Standard Deviation 9.71
6.26 uV
Standard Deviation 4.17
Sensory Median Nerve Amplitude
24 weeks
4.31 uV
Standard Deviation 6.56
4.52 uV
Standard Deviation 4.47
6.06 uV
Standard Deviation 8.12
4.97 uV
Standard Deviation 4.41

PRIMARY outcome

Timeframe: Baseline, 12wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sensory Median Nerve Latency
Baseline
2.26 ms
Standard Deviation 1.83
1.66 ms
Standard Deviation 2.05
1.76 ms
Standard Deviation 2.06
3.36 ms
Standard Deviation 1.75
Sensory Median Nerve Latency
12 weeks
2.19 ms
Standard Deviation 2.11
1.54 ms
Standard Deviation 1.99
2.00 ms
Standard Deviation 2.36
3.15 ms
Standard Deviation 1.75
Sensory Median Nerve Latency
24 weeks
1.81 ms
Standard Deviation 1.99
2.72 ms
Standard Deviation 2.07
2.44 ms
Standard Deviation 2.43
2.87 ms
Standard Deviation 2.03

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sensory Median Nerve Conduction Velocity
Baseline
30.49 m/s
Standard Deviation 25.08
18.95 m/s
Standard Deviation 23.83
20.34 m/s
Standard Deviation 23.59
35.05 m/s
Standard Deviation 18.19
Sensory Median Nerve Conduction Velocity
12 weeks
23.64 m/s
Standard Deviation 22.93
18.18 m/s
Standard Deviation 23.73
19.04 m/s
Standard Deviation 22.17
35.73 m/s
Standard Deviation 19.8
Sensory Median Nerve Conduction Velocity
24 weeks
22.88 m/s
Standard Deviation 25.21
30.00 m/s
Standard Deviation 22.74
22.90 m/s
Standard Deviation 22.63
29.76 m/s
Standard Deviation 21.03

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sensory Ulnar Nerve Amplitude
Baseline
7.75 uV
Standard Deviation 5.77
4.48 uV
Standard Deviation 4.08
4.95 uV
Standard Deviation 5.10
5.60 uV
Standard Deviation 7.63
Sensory Ulnar Nerve Amplitude
12 weeks
8.49 uV
Standard Deviation 5.89
4.68 uV
Standard Deviation 4.84
4.44 uV
Standard Deviation 6.71
3.87 uV
Standard Deviation 5.41
Sensory Ulnar Nerve Amplitude
24 weeks
8.68 uV
Standard Deviation 6.89
6.08 uV
Standard Deviation 5.12
4.12 uV
Standard Deviation 2.88
6.97 uV
Standard Deviation 6.17

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sensory Ulnar Nerve Latency
Baseline
2.46 ms
Standard Deviation 1.26
2.25 ms
Standard Deviation 1.73
1.78 ms
Standard Deviation 1.72
1.50 ms
Standard Deviation 1.76
Sensory Ulnar Nerve Latency
24 weeks
2.24 ms
Standard Deviation 1.45
2.56 ms
Standard Deviation 1.47
2.53 ms
Standard Deviation 1.66
2.36 ms
Standard Deviation 1.66
Sensory Ulnar Nerve Latency
12 weeks
2.36 ms
Standard Deviation 1.39
1.82 ms
Standard Deviation 1.58
1.49 ms
Standard Deviation 1.75
1.24 ms
Standard Deviation 1.64

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Sensory Ulnar Nerve Conduction Velocity
Baseline
39.27 m/s
Standard Deviation 20.14
29.29 m/s
Standard Deviation 22.19
24.68 m/s
Standard Deviation 23.94
20.61 m/s
Standard Deviation 24.06
Sensory Ulnar Nerve Conduction Velocity
12 weeks
36.40 m/s
Standard Deviation 20.87
23.64 m/s
Standard Deviation 25.03
20.59 m/s
Standard Deviation 23.99
19.81 m/s
Standard Deviation 25.83
Sensory Ulnar Nerve Conduction Velocity
24 weeks
36.06 m/s
Standard Deviation 23.31
34.10 m/s
Standard Deviation 19.48
30.91 m/s
Standard Deviation 20.12
31.54 m/s
Standard Deviation 22.09

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Peroneal Nerve Amplitude
Baseline
2.79 mV
Standard Deviation 1.91
2.16 mV
Standard Deviation 2.17
2.33 mV
Standard Deviation 2.01
1.89 mV
Standard Deviation 1.68
Peroneal Nerve Amplitude
12 weeks
2.52 mV
Standard Deviation 1.47
1.89 mV
Standard Deviation 2.27
1.55 mV
Standard Deviation 1.51
1.43 mV
Standard Deviation 1.35
Peroneal Nerve Amplitude
24 weeks
2.71 mV
Standard Deviation 1.97
2.45 mV
Standard Deviation 2.72
1.70 mV
Standard Deviation 1.51
1.75 mV
Standard Deviation 1.73

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 7 at 6 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Peroneal Nerve Latency
Baseline
4.65 ms
Standard Deviation 1.88
4.69 ms
Standard Deviation 2.58
4.93 ms
Standard Deviation 1.95
4.96 ms
Standard Deviation 1.88
Peroneal Nerve Latency
12 weeks
5.06 ms
Standard Deviation 2.17
4.49 ms
Standard Deviation 2.72
4.85 ms
Standard Deviation 1.72
4.52 ms
Standard Deviation 2.46
Peroneal Nerve Latency
24 weeks
4.68 ms
Standard Deviation 2.20
4.69 ms
Standard Deviation 3.10
4.63 ms
Standard Deviation 1.65
5.28 ms
Standard Deviation 2.14

PRIMARY outcome

Timeframe: Baseline, 12 wks, 24 wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 1) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. No data recorded for 1 Sedentary subject at 3 month evaluation. Data shown include responders and non-responders.

Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Peroneal Nerve Conduction Velocity
Baseline
33.33 m/s
Standard Deviation 11.82
30.58 m/s
Standard Deviation 14.92
32.01 m/s
Standard Deviation 11.82
32.97 m/s
Standard Deviation 13.59
Peroneal Nerve Conduction Velocity
12 weeks
33.86 m/s
Standard Deviation 13.28
29.07 m/s
Standard Deviation 16.98
32.56 m/s
Standard Deviation 11.15
29.46 m/s
Standard Deviation 16.19
Peroneal Nerve Conduction Velocity
24 weeks
33.08 m/s
Standard Deviation 13.69
29.41 m/s
Standard Deviation 17.28
33.40 m/s
Standard Deviation 11.56
31.06 m/s
Standard Deviation 12.27

SECONDARY outcome

Timeframe: Initial entry into study, 12 and 24 weeks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#1) eval. Subj. withdrawn from study by PI/co-PI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) post 24 week EMG and withdrawn s/p hosp.

Changes in blood glucose in response to modified Bruce Protocol treadmill test (TMT)

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Symptom-Limited TMT Blood Glucose Response
Baseline-Pre Exercise
180.7 mg/dl
Standard Deviation 43.2
157.3 mg/dl
Standard Deviation 49.5
188.6 mg/dl
Standard Deviation 65.6
181.5 mg/dl
Standard Deviation 48.9
Symptom-Limited TMT Blood Glucose Response
Baseline-Post Exercise
149.5 mg/dl
Standard Deviation 46.1
129.3 mg/dl
Standard Deviation 41.7
169.4 mg/dl
Standard Deviation 46.0
138.5 mg/dl
Standard Deviation 48.7
Symptom-Limited TMT Blood Glucose Response
12-weeks-Pre Exercise
160.0 mg/dl
Standard Deviation 51.2
188.7 mg/dl
Standard Deviation 68.6
171.7 mg/dl
Standard Deviation 47.9
170.6 mg/dl
Standard Deviation 43.9
Symptom-Limited TMT Blood Glucose Response
12-weeks-Post Exercise
128.0 mg/dl
Standard Deviation 28.7
127.3 mg/dl
Standard Deviation 36.0
151.1 mg/dl
Standard Deviation 41.4
147.2 mg/dl
Standard Deviation 59.7
Symptom-Limited TMT Blood Glucose Response
24-weeks-Pre Exercise
169.0 mg/dl
Standard Deviation 48.9
163.9 mg/dl
Standard Deviation 46.0
181.8 mg/dl
Standard Deviation 62.9
187.9 mg/dl
Standard Deviation 53.6
Symptom-Limited TMT Blood Glucose Response
24-weeks-Post Exercise
139.4 mg/dl
Standard Deviation 45.9
143.6 mg/dl
Standard Deviation 33.8
166.3 mg/dl
Standard Deviation 57.9
161.9 mg/dl
Standard Deviation 43.5

SECONDARY outcome

Timeframe: Initial entry into study, 12 and 24 weeks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#1) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) post 24 week EMG and withdrawn s/p hosp.

The short form-36Veterans (SF-36V) health survey questionnaire was used to measure health-related quality of life. This survey is comprised of eight subscales and two overall component scores, all of which have demonstrated high levels of internal consistency and discriminate validity when administered to groups of medically stable individuals. Patient aggregate responses for the eight distinct summary subscales and two component scores were compiled as a percentage of total points possible using the RAND 36-item health survey table. Data shown are expressed as a percentage of total possible score ranging from 0%-100% with 100% considered relatively good health and 0% considered poor health. Physical Component scores reflect perceived changes in physical health relative to the previous year.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Short Form-36V: Physical Component Score
Baseline
59.1 score on a scale
Standard Deviation 28.0
60.4 score on a scale
Standard Deviation 29.1
52.3 score on a scale
Standard Deviation 26.1
56.8 score on a scale
Standard Deviation 25.2
Short Form-36V: Physical Component Score
12-weeks
72.2 score on a scale
Standard Deviation 29.2
57.5 score on a scale
Standard Deviation 23.7
86.4 score on a scale
Standard Deviation 17.2
65.0 score on a scale
Standard Deviation 26.9
Short Form-36V: Physical Component Score
24-weeks
75.0 score on a scale
Standard Deviation 32.3
58.3 score on a scale
Standard Deviation 21.7
86.4 score on a scale
Standard Deviation 17.2
77.5 score on a scale
Standard Deviation 32.2

SECONDARY outcome

Timeframe: baseline, 12-wks, 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) fell post 24 week EMG and withdrawn s/p hosp.

Total time subjects voluntarily exercised while undergoing a modified Bruce Protocol treadmill test (TMT)

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Voluntary Duration of Symptom-Limited TMT
Baseline
11.0 minutes
Standard Deviation 3.5
10.8 minutes
Standard Deviation 3.5
11.9 minutes
Standard Deviation 2.2
8.8 minutes
Standard Deviation 2.9
Voluntary Duration of Symptom-Limited TMT
12-weeks
13.0 minutes
Standard Deviation 4.4
10.7 minutes
Standard Deviation 3.8
13.4 minutes
Standard Deviation 2.5
9.3 minutes
Standard Deviation 3.0
Voluntary Duration of Symptom-Limited TMT
24-weeks
14.2 minutes
Standard Deviation 2.8
11.4 minutes
Standard Deviation 3.9
13.3 minutes
Standard Deviation 2.9
9.0 minutes
Standard Deviation 2.9

SECONDARY outcome

Timeframe: baseline, 12-wks, 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) fell post 24 week EMG and withdrawn s/p hosp.

Peak heart rate achieved while undergoing a modified Bruce Protocol treadmill test (TMT)

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Symptom-Limited TMT Maximum Heart Rate
Baseline
146.0 beats per min
Standard Deviation 23.3
128.5 beats per min
Standard Deviation 31.9
141.5 beats per min
Standard Deviation 18.9
135.5 beats per min
Standard Deviation 26.6
Symptom-Limited TMT Maximum Heart Rate
12-weeks
135.9 beats per min
Standard Deviation 25.4
125.8 beats per min
Standard Deviation 37.9
143.1 beats per min
Standard Deviation 21.6
126.0 beats per min
Standard Deviation 24.9
Symptom-Limited TMT Maximum Heart Rate
24-weeks
143.3 beats per min
Standard Deviation 16.8
127.4 beats per min
Standard Deviation 29.3
140.5 beats per min
Standard Deviation 24.1
129.3 beats per min
Standard Deviation 21.4

SECONDARY outcome

Timeframe: Baseline, 12-wk, 24-wk

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) fell post 24 week EMG and withdrawn s/p hosp.

Peak systolic BP achieved while undergoing a modified Bruce Protocol treadmill test (TMT)

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Symptom-Limited TMT Maximum Systolic Blood Pressure
Baseline
188.4 mmHg
Standard Deviation 20.4
190.5 mmHg
Standard Deviation 26.5
189.3 mmHg
Standard Deviation 26.7
196.3 mmHg
Standard Deviation 25.5
Symptom-Limited TMT Maximum Systolic Blood Pressure
12-weeks
184.0 mmHg
Standard Deviation 29.8
196.0 mmHg
Standard Deviation 19.8
185.8 mmHg
Standard Deviation 17.8
200.0 mmHg
Standard Deviation 28.6
Symptom-Limited TMT Maximum Systolic Blood Pressure
24-weeks
185.3 mmHg
Standard Deviation 9.9
179.1 mmHg
Standard Deviation 13.9
180.7 mmHg
Standard Deviation 20.6
193.1 mmHg
Standard Deviation 21.4

SECONDARY outcome

Timeframe: Baseline, 12-wks, 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) fell post 24 week EMG and withdrawn s/p hosp.

Peak volume of air exchanged per minute achieved while undergoing a modified Bruce Protocol treadmill test (TMT)

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Symptom-Limited TMT Maximum Minute Ventilation (VE)
12-weeks
62.4 liters/min
Standard Deviation 15.5
59.9 liters/min
Standard Deviation 10.6
67.0 liters/min
Standard Deviation 22.2
60.6 liters/min
Standard Deviation 12.1
Symptom-Limited TMT Maximum Minute Ventilation (VE)
Baseline
62.0 liters/min
Standard Deviation 13.3
62.9 liters/min
Standard Deviation 15.3
63.5 liters/min
Standard Deviation 18.8
54.3 liters/min
Standard Deviation 12.9
Symptom-Limited TMT Maximum Minute Ventilation (VE)
24-weeks
68.8 liters/min
Standard Deviation 13.1
57.4 liters/min
Standard Deviation 13.1
73.2 liters/min
Standard Deviation 27.3
56.4 liters/min
Standard Deviation 12.4

SECONDARY outcome

Timeframe: Baseline, 12-wks, 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) fell post 24 week EMG and withdrawn s/p hosp.

Peak Oxygen uptake achieved while undergoing a modified Bruce Protocol treadmill test (TMT)

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Symptom-Limited TMT Maximum Oxygen Uptake (VO2)
Baseline
18.9 ml/min/kg
Standard Deviation 3.6
17.4 ml/min/kg
Standard Deviation 3.9
18.9 ml/min/kg
Standard Deviation 4.2
16.5 ml/min/kg
Standard Deviation 3.8
Symptom-Limited TMT Maximum Oxygen Uptake (VO2)
12-weeks
18.9 ml/min/kg
Standard Deviation 4.7
17.0 ml/min/kg
Standard Deviation 4.6
18.7 ml/min/kg
Standard Deviation 5.1
17.2 ml/min/kg
Standard Deviation 3.0
Symptom-Limited TMT Maximum Oxygen Uptake (VO2)
24-weeks
21.8 ml/min/kg
Standard Deviation 3.4
18.2 ml/min/kg
Standard Deviation 4.6
19.3 ml/min/kg
Standard Deviation 5.3
16.5 ml/min/kg
Standard Deviation 2.2

SECONDARY outcome

Timeframe: Baseline, 12-wks, 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) post 24 week EMG and withdrawn s/p hosp.

Peak RER achieved while undergoing a modified Bruce Protocol treadmill test (TMT). This is a mathematical ratio of maximally achieved (peak) VCO2 divided by maximally achieved (peak) VO2.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Maximum Respiratory Exchange Ratio (RER) During TMT
Baseline
1.1 ratio
Standard Deviation 0.1
1.2 ratio
Standard Deviation 0.1
1.2 ratio
Standard Deviation 0.2
1.1 ratio
Standard Deviation 0.1
Maximum Respiratory Exchange Ratio (RER) During TMT
12-weeks
1.2 ratio
Standard Deviation 0.1
1.2 ratio
Standard Deviation 0.1
1.2 ratio
Standard Deviation 0.1
1.2 ratio
Standard Deviation 0.1
Maximum Respiratory Exchange Ratio (RER) During TMT
24-weeks
1.1 ratio
Standard Deviation 0.0
1.2 ratio
Standard Deviation 0.1
1.2 ratio
Standard Deviation 0.1
1.1 ratio
Standard Deviation 0.1

SECONDARY outcome

Timeframe: Baseline, 12-wks, 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) fell post 24 week EMG and withdrawn s/p hosp.

Peak Carbon Dioxide expelled achieved while undergoing a modified Bruce Protocol treadmill test (TMT)

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Symptom-Limited TMT Maximum Carbon Dioxide Expelled (VCO2)
Baseline
20.7 ml/min/kg
Standard Deviation 4.1
20.4 ml/min/kg
Standard Deviation 4.7
22.0 ml/min/kg
Standard Deviation 6.4
18.9 ml/min/kg
Standard Deviation 5.4
Symptom-Limited TMT Maximum Carbon Dioxide Expelled (VCO2)
12-weeks
23.7 ml/min/kg
Standard Deviation 7.4
19.7 ml/min/kg
Standard Deviation 4.9
21.9 ml/min/kg
Standard Deviation 7.3
19.9 ml/min/kg
Standard Deviation 3.9
Symptom-Limited TMT Maximum Carbon Dioxide Expelled (VCO2)
24-weeks
23.4 ml/min/kg
Standard Deviation 4.8
20.2 ml/min/kg
Standard Deviation 6.3
22.5 ml/min/kg
Standard Deviation 7.1
18.7 ml/min/kg
Standard Deviation 3.4

SECONDARY outcome

Timeframe: Baseline, 12-wks, 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#2) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) fell post 24 week EMG and withdrawn s/p hosp.

Peak metabolic rate equivalents (METS) achieved while undergoing a modified Bruce Protocol treadmill test (TMT). One MET is defined as the metabolic rate observed at rest, quantified as resting oxygen consumption of 250 ml/min (Male) or 200 ml /min (female). A value of 5 METS would represent a metabolic rate that is 5x that at rest and is considered an indicator of how hard a given individual is exercising. Data shown are expressed as a ratio at peak of exercise of oxygen consumed relative to normalized values for men or women at rest.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Symptom-Limited TMT Maximum METS Achieved (MET)
Baseline
5.4 ratio
Standard Deviation 1.0
5.0 ratio
Standard Deviation 1.1
5.4 ratio
Standard Deviation 1.2
4.7 ratio
Standard Deviation 1.1
Symptom-Limited TMT Maximum METS Achieved (MET)
12-weeks
5.6 ratio
Standard Deviation 1.3
4.9 ratio
Standard Deviation 1.3
5.4 ratio
Standard Deviation 1.4
4.9 ratio
Standard Deviation 0.9
Symptom-Limited TMT Maximum METS Achieved (MET)
24-weeks
5.9 ratio
Standard Deviation 1.2
5.2 ratio
Standard Deviation 1.3
5.5 ratio
Standard Deviation 1.5
4.8 ratio
Standard Deviation 0.6

SECONDARY outcome

Timeframe: initial entry into study, and at 12-wks and 24-wks

Population: Subj. withdrew from study prior to 3 mo. (#3) and 6 mo. (#1) eval. Subj. withdrawn from study by PI/coPI prior to 3 month (#2) and 6 month (#1) eval. Total difference = 8 at 6 mo. eval. 1(Sed) had EMG @ 12 and 24 wks didn't receive clearance for TMT but to continue in other study activities. 1 (Sed) post 24 week EMG and withdrawn s/p hosp.

The short form-36Veterans (SF-36V) health survey questionnaire was used to measure health-related quality of life. This survey is comprised of eight subscales and two overall component scores, all of which have demonstrated high levels of internal consistency and discriminate validity when administered to groups of medically stable individuals. Patient aggregate responses for the eight distinct summary subscales and two component scores were compiled as a percentage of total points possible using the RAND 36-item health survey table. Data shown are expressed as a percentage of total possible score ranging from 0%-100% with 100% considered relatively good health and 0% considered poor health. Mental Component scores reflect perceived changes in emotional health relative to the previous year.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Short Form-36V: Mental Component Score
Baseline
61.4 score on a scale
Standard Deviation 28.2
68.8 score on a scale
Standard Deviation 32.2
63.6 score on a scale
Standard Deviation 30.3
59.1 score on a scale
Standard Deviation 25.7
Short Form-36V: Mental Component Score
12-wks
72.2 score on a scale
Standard Deviation 26.4
65.0 score on a scale
Standard Deviation 17.5
72.7 score on a scale
Standard Deviation 20.8
60.0 score on a scale
Standard Deviation 26.9
Short Form-36V: Mental Component Score
24-wks
75.0 score on a scale
Standard Deviation 25.0
75.0 score on a scale
Standard Deviation 21.7
75.0 score on a scale
Standard Deviation 19.4
67.5 score on a scale
Standard Deviation 33.4

OTHER_PRE_SPECIFIED outcome

Timeframe: baseline

Height of subjects upon entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Height
177.4 cm
Standard Deviation 7.1
178.1 cm
Standard Deviation 5.8
181.0 cm
Standard Deviation 8.6
179.9 cm
Standard Deviation 5.3

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 12-wks, 24-wks

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 2) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 8 at 6 month evaluation.

Weight of subjects at baseline, 12-weeks, and 24-weeks

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Weight
Baseline
101.3 kg
Standard Deviation 14.4
104.7 kg
Standard Deviation 14.4
109.9 kg
Standard Deviation 19.7
102.6 kg
Standard Deviation 16.3
Weight
12-wks
97.1 kg
Standard Deviation 9.7
103.7 kg
Standard Deviation 12.9
109.8 kg
Standard Deviation 18.5
102.9 kg
Standard Deviation 17
Weight
24-wks
98.4 kg
Standard Deviation 10.7
100.5 kg
Standard Deviation 10.5
109.8 kg
Standard Deviation 18.3
103.8 kg
Standard Deviation 17.6

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 12-wk, 24-wk

Population: Subjects withdrew from study prior to 3 month (# 3) and 6 month (# 2) evaluation Subjects were withdrawn from study by principal/ co-principal investigator prior to 3 month (# 2) and 6 month (# 1) evaluation. Total difference = 8 at 6 month evaluation.

BMI is calculated as a ratio of subject body mass (kg) divided by the square of subject height (m).

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Body Mass Index (BMI)
Baseline
32.4 kg/m^2
Standard Deviation 6.3
32.9 kg/m^2
Standard Deviation 3.5
33.4 kg/m^2
Standard Deviation 5.4
31.5 kg/m^2
Standard Deviation 4.1
Body Mass Index (BMI)
12-wk
30.8 kg/m^2
Standard Deviation 4.0
32.3 kg/m^2
Standard Deviation 2.8
33.4 kg/m^2
Standard Deviation 5.0
31.6 kg/m^2
Standard Deviation 4.2
Body Mass Index (BMI)
24-wk
31.5 kg/m^2
Standard Deviation 3.8
31.5 kg/m^2
Standard Deviation 2.6
33.4 kg/m^2
Standard Deviation 4.9
31.9 kg/m^2
Standard Deviation 4.3

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Duration, in years, since first diagnosed with Diabetes Mellitus upon entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Duration of Diabetes Mellitus
8.9 years
Standard Deviation 6.3
12.6 years
Standard Deviation 11.1
10.9 years
Standard Deviation 4.1
10.1 years
Standard Deviation 6.7

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 12-wk, 24-wk

Population: A1c testing was performed prior to EMG evaluation so there are 2/4 additional values for 3/6 month numbers of subjects than is reflected in the statement regarding subject withdrawal in the EMG sections. Total difference = 6 at 6 month evaluation.

Laboratory values of subject HbA1C levels at Baseline, 12-wk, 24-wk

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
HbA1C Laboratory Values
Baseline
7.2 percentage of Hb
Standard Deviation 0.7
7.8 percentage of Hb
Standard Deviation 0.5
8.0 percentage of Hb
Standard Deviation 1.0
8.0 percentage of Hb
Standard Deviation 1.0
HbA1C Laboratory Values
12-wk
7.3 percentage of Hb
Standard Deviation 1.0
7.7 percentage of Hb
Standard Deviation 1.0
8.0 percentage of Hb
Standard Deviation 1.5
7.4 percentage of Hb
Standard Deviation 1.0
HbA1C Laboratory Values
24-wk
7.1 percentage of Hb
Standard Deviation 0.7
7.2 percentage of Hb
Standard Deviation 1.1
7.9 percentage of Hb
Standard Deviation 1.3
8.0 percentage of Hb
Standard Deviation 1.2

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Laboratory triglyceride values at baseline entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Triglyceride Laboratory Values
162.0 mg/dL
Standard Deviation 60
157.7 mg/dL
Standard Deviation 84.5
125.0 mg/dL
Standard Deviation 57.1
144.5 mg/dL
Standard Deviation 68.2

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Laboratory total cholesterol, HDL-cholesterol, and LDL-cholesterol levels at baseline entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Cholesterol Laboratory Values
Total Cholesterol
159.9 mg/dL
Standard Deviation 48.7
139.3 mg/dL
Standard Deviation 25.1
156.4 mg/dL
Standard Deviation 36.2
158.5 mg/dL
Standard Deviation 39.7
Cholesterol Laboratory Values
HDL-Cholesterol
38.4 mg/dL
Standard Deviation 4.8
41.4 mg/dL
Standard Deviation 29.0
42.8 mg/dL
Standard Deviation 13.5
40.7 mg/dL
Standard Deviation 14.0
Cholesterol Laboratory Values
LDL-Cholesterol
89.2 mg/dL
Standard Deviation 48.0
68.4 mg/dL
Standard Deviation 23.3
88.6 mg/dL
Standard Deviation 31.2
89.0 mg/dL
Standard Deviation 42.5

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Laboratory creatinine values at baseline entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Creatinine Laboratory Values
1.0 mg/dL
Standard Deviation 0.2
1.1 mg/dL
Standard Deviation 0.2
1.0 mg/dL
Standard Deviation 0.1
0.9 mg/dL
Standard Deviation 0.1

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Laboratory Blood Urea Nitrogen levels at baseline entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Blood Urea Nitrogen (BUN) Laboratory Values
17.8 mg/dL
Standard Deviation 5.6
17.0 mg/dL
Standard Deviation 5.5
19.0 mg/dL
Standard Deviation 5.9
16.5 mg/dL
Standard Deviation 6.7

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Laboratory values for Aspartate Aminotransferase (AST) at baseline entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Aspartate Aminotransferase Laboratory Values
23.6 units/L
Standard Deviation 15.2
20.8 units/L
Standard Deviation 5.6
13.5 units/L
Standard Deviation 6.3
19.5 units/L
Standard Deviation 9.6

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Laboratory values for Thyroid Stimulating Hormone (TSH) at baseline entry into study

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Thyroid Stimulating Hormone Laboratory Values
1.8 uIU/mL
Standard Deviation 0.7
1.3 uIU/mL
Standard Deviation 0.6
1.8 uIU/mL
Standard Deviation 0.9
2.0 uIU/mL
Standard Deviation 1.6

OTHER_PRE_SPECIFIED outcome

Timeframe: at baseline

Age of participants at entry into study.

Outcome measures

Outcome measures
Measure
Combined Aerobic and Strength Exercise Group
n=11 Participants
Combined Aerobic and Isokinetic Strength Exercise Group Exercise: Structured aerobic exercise (treadmill). Exercise: Structured isokinetic strength exercise (dynameter).
Sedentary Control Group
n=12 Participants
Sedentary Control Group
Aerobic Exercise Group
n=11 Participants
Aerobic Exercise Group Exercise: Structured aerobic exercise (treadmill).
Strength Exercise Group
n=11 Participants
Strength Exercise Group Exercise: Structured isokinetic strength exercise (dynameter).
Age
63.0 years
Standard Deviation 6.6
61.0 years
Standard Deviation 7.0
61.9 years
Standard Deviation 8.3
64.2 years
Standard Deviation 9.5

Adverse Events

Sedentary

Serious events: 6 serious events
Other events: 0 other events
Deaths: 6 deaths

Aerobic Exercise

Serious events: 4 serious events
Other events: 0 other events
Deaths: 4 deaths

Strength Exercise

Serious events: 4 serious events
Other events: 0 other events
Deaths: 4 deaths

Combined Aerobic and Strength

Serious events: 5 serious events
Other events: 0 other events
Deaths: 5 deaths

Serious adverse events

Serious adverse events
Measure
Sedentary
n=12 participants at risk
Sedentary Control Group
Aerobic Exercise
n=11 participants at risk
Structured aerobic exercise (treadmill)
Strength Exercise
n=11 participants at risk
Structured isokinetic strength exercise (dynameter).
Combined Aerobic and Strength
n=11 participants at risk
Structured aerobic exercise (treadmill) and structured isokinetic strength exercise (dynameter).
Surgical and medical procedures
4 years 6 months
50.0%
6/12 • Number of events 11 • 5 years
36.4%
4/11 • Number of events 4 • 5 years
36.4%
4/11 • Number of events 9 • 5 years
45.5%
5/11 • Number of events 9 • 5 years

Other adverse events

Adverse event data not reported

Additional Information

Evan Stubbs

Edward Hines Jr. VA Hospital

Phone: 708-202-3507

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place